Quadira Biosciences develops therapeutic antibody-drug conjugates (ADCs) using a novel click chemistry approach and a physiological 3D cell culture system to enhance preclinical evaluation efficiency. This technology enables the rapid development of ADCs, significantly reducing the time to market while improving efficacy and safety profiles compared to existing treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Developing antibody-drug conjugates (ADCs) is a time-consuming process, and current preclinical evaluation methods may not accurately predict efficacy and safety in humans. This can lead to delays in bringing new ADCs to market and potentially limit their therapeutic potential.
Solution
Quadira Biosciences accelerates ADC development by integrating a novel click chemistry approach with a physiological 3D cell culture system for preclinical evaluation. This combination enables rapid design, screening, and characterization of highly effective ADCs. The 3D cell culture system provides a more physiologically relevant environment than traditional 2D cultures, improving the accuracy of preclinical predictions. The company's lead ADC product, QBK249-G, targets HER2-positive solid tumors and has demonstrated enhanced antitumor activity and biotolerability in preclinical studies.
Target Audience
Quadira Biosciences' primary customers are pharmaceutical companies and research institutions involved in the development of novel cancer therapeutics, particularly ADCs.
Features
- Novel click chemistry platform for efficient ADC synthesis and conjugation
- Proprietary 3D cell culture system mimicking the in-vivo tumor microenvironment
- Accelerated preclinical evaluation process, reducing development timelines
- QBK249-G: a HER2-targeting ADC with potent antitumor activity against HER2-positive solid tumors
- Demonstrated 8-fold higher antitumor efficacy compared to a currently marketed ADC at a comparable toxicity at a 10-fold lower concentration in preclinical studies
- Proven ability to effectively kill dormant tumor cells